Skip to main content

Adtalem Accelerates $150 Million Share Repurchase Program

Company to Actively Deploy Share Repurchase Authorization Reflecting Confidence in Company’s Fundamental Strength

Reaffirms Fiscal Year 2026 Outlook

Adtalem Global Education Inc. (NYSE: ATGE), the largest healthcare educator in the United States, today announced plans to accelerate execution against its remaining $136 million balance under its existing $150 million board authorized share repurchase program1, reflecting its current financial strength through revenue and profit growth as well as confidence in the Company’s long-term outlook.

“Adtalem’s Board of Directors and management remain confident in the Company’s strategic position and long-term outlook. We continue to deliver strong results—with total enrollment increasing 8% year-over-year and revenue up 10.8% year-over-year for the first quarter. Industry trends around healthcare workforce development also remain highly favorable,” said Steve Beard, chairman and chief executive officer, Adtalem Global Education. “Accelerating our share repurchase activity underscores our conviction in our strategy, and current market prices present an attractive use of capital.”

The Company reaffirmed its guidance for fiscal year 2026, with revenue expected to be in the range of $1,900 million to $1,940 million or approximately 6.0% to 8.5% growth year-over-year, and adjusted earnings per share anticipated to be in the range of $7.60 to $7.90, or approximately 14.0% to 18.5% growth year-over-year.

“We have substantial financial capacity and flexibility to continue returning capital to shareholders, while simultaneously investing in our growth initiatives and maintaining our strong balance sheet,” said Bob Phelan, chief financial officer, Adtalem Global Education.

Adtalem will host an Investor Day where it plans to provide a comprehensive strategic and operational update, scheduled for February 24, 2026. Additional information can be found at investors.adtalem.com.

1 The accelerated activity will remain within Adtalem’s previously announced $150 million Board-authorized share repurchase program through May 2028. The Company has over $136 million remaining under the program and repurchases can be made from time to time using a variety of methods, which may include open market purchases, privately negotiated transactions or otherwise, all in accordance with the rules of the Securities and Exchange Commission and other applicable legal requirements. The specific timing, price and size of purchases will depend on prevailing stock prices, general economic and market conditions, and other considerations.

About Adtalem Global Education

Adtalem Global Education is the largest provider of healthcare education in the U.S., shaping the future of healthcare by preparing a dynamic workforce with high-quality academic programs. We innovate education pathways, align with industry needs and empower individuals to reach their full potential. Our commitment to excellence and access is reflected in our expansive network of institutions, serving over 97,000 students and supported by a strong community of approximately 365,000 alumni and over 10,000 dedicated employees.

CAUTIONARY DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Adtalem’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “potential,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. Important factors that could cause actual results to differ materially from the expectations expressed or implied by our forward-looking statements are disclosed in Item 1A. “Risk Factors,” of our Annual Report on Form 10-K. You should evaluate forward-looking statements in the context of these risks and uncertainties and are cautioned to not place undue reliance on such forward-looking statements. We caution you that factors, performance or developments we expect or anticipate may not occur as we expect or, even if substantially realized, may not affect us or our operations in the way we expect. All forward-looking statements are based on information available as of the date any such statements are made, and Adtalem assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.32
+0.00 (0.00%)
AAPL  270.04
+0.00 (0.00%)
AMD  250.05
+0.00 (0.00%)
BAC  53.54
+0.00 (0.00%)
GOOG  278.06
+0.00 (0.00%)
META  627.32
+0.00 (0.00%)
MSFT  514.33
+0.00 (0.00%)
NVDA  198.69
+0.00 (0.00%)
ORCL  248.17
+0.00 (0.00%)
TSLA  444.26
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.